TB-500 and thymosin beta-4: the fragment versus the protein

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

Coming back to post #16, because the follow-up matters more than the original answer.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.

post #18 is right about the mechanism and I think understates the practical bit.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and the distinction matters, but it also means treatment plans based on these compounds are being built on theoretical grounds, not empirical ones.

For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or recommend these compounds.

Picking up post #21: that is the part I would want checked first.

What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

I read post #25 twice before replying, because I had assumed the opposite.

TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.

This follows post #25 rather than contradicting it.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

On post #25 — agreed on the reasoning, with one qualification.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

post #29 answers the question as asked. The question underneath it is different.

Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.